HealthPhoto: News18 WorldPersonalised mRNA Cancer Vaccine Cuts Melanoma Recurrence by 49%
A personalised mRNA cancer vaccine, mRNA-4157 (V940), combined with standard immunotherapy, has reduced the risk of melanoma recurrence or death by 49% over three years in a phase 3 trial. The vaccine is tailored to each patient's tumour DNA, targeting up to 34 unique neoantigens to boost immune response after surgical removal of high-risk stage III or IV melanoma.
News18 World·


